Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Betamethasone valerate 0.1% ointment	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Betnovate®. Potent potency.
Betamethasone valerate 0.1% scalp application	TA85 - Frequency of application of topical corticosteroids for atopic eczema	Betnovate®. Potent potency.
Bevacizumab (Avastin®) injection	TA298 - Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
Bevacizumab infusion (Avastin®)	TA178 - Bevacizumab (first-line), sorafenib (first and second line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma TA212 - Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer TA242 - Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab (monotherapy or combination chemotherapy), bevacizumab (in combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy TA214 - Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer TA263 - Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer TA284 - Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer TA285 - Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer	Negative NICE TA & hospital use only.
Bimekizumab	TA723 - Bimekizumab for treating moderate to severe plaque psoriasis TA916 - Bimekizumab for treating active psoriatic arthritis
Blinatumomab	TA450 - Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia TA589 - Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity	Hospital use only
Bortezomib injection	TA228 - Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia TA129 - Bortezomib monotherapy for relapsed multiple myeloma TA311 - Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation	National CDF list. Hospital use only.
Bosutinib	TA311 - Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Botox A	TA260 - Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Brentuximab injection	TA446 - Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma TA478 - Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma TA577 - Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma TA641 - Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma	National CDF list. For hospital use only.

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.